The evolving atopic dermatitis management landscape

References

• Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218–1233.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
   PubMed Web of Science ®Google Scholar
• Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.
   PubMedGoogle Scholar
• Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250.
   PubMedGoogle Scholar
• Xie QW, Dai X, Tang X, et al. Risk of mental disorders in children and adolescents with atopic dermatitis: a systematic review and meta-analysis. Front Psychol. 2019;10:1773.
   PubMed Web of Science ®Google Scholar
• Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy. 2015;45(3):566–574.
   PubMed Web of Science ®Google Scholar
• Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989;151:7–10. discussion 47-52.
   PubMedGoogle Scholar
• Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(2):410–419.e3.
   PubMed Web of Science ®Google Scholar
• Fishbein AB, Mueller K, Lor J, et al. Systematic review and meta-analysis comparing topical corticosteroids with vehicle/moisturizer in childhood atopic dermatitis. J Pediatr Nurs. 2019;47:36–43.
   PubMed Web of Science ®Google Scholar
• Gutfreund K, Bienias W, Szewczyk A, et al. Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165–169.
   PubMed Web of Science ®Google Scholar
• Chia BK, Tey HL. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis. 2015;26(3):122–132.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–18.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bissonnette R, Eichenfield LF, et al. The validated investigator global assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis. Br J Dermatol. 2021;184(1):87–95.
   PubMed Web of Science ®Google Scholar
• Hong CH, Gooderham M, Bissonnette R. Evidence review of topical calcineurin inhibitors for the treatment of adult atopic dermatitis. J Cutan Med Surg. 2019;23(4_suppl):5S–10S.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14(3):163–178.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159(4):942–951.
   PubMed Web of Science ®Google Scholar
• Russell G, Graveley R, Seid J, et al. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheum. 1992;21(6 Suppl 3):16–22.
   PubMed Web of Science ®Google Scholar
• Severity scoring of atopic dermatitis: the SCORAD index. consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31.
   PubMed Web of Science ®Google Scholar
• Haw S, Shin MK, Haw CR. The efficacy and safety of long-term Oral Cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol. 2010;22(1):9–15.
   PubMed Web of Science ®Google Scholar
• Hijnen DJ, Ten Berge O, Timmer-de Mik L, et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007;21(1):85–89.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619.
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol. 2014;133(2):429–438.
   PubMed Web of Science ®Google Scholar
• Schneeweiss MC, Perez-Chada L, and Merola JF. Comparative safety of systemic immuno-modulatory medications in adults with atopic dermatitis. J Am Acad Dermatol. 2019;85(2):321–329 .
   Web of Science ®Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324–330.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839–846.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol. 1996;135(Suppl 48):25–30.
   PubMedGoogle Scholar
• Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol. 2008;33(6):710–711.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–359.
   PubMed Web of Science ®Google Scholar
• Nedelcu RI, Balaban M, Turcu G, et al. Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: three case reports. Exp Ther Med. 2019;18(2):905–910.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Wulf HC. The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis. Acta Derm Venereol. 1997;77(5):392–393.
   PubMed Web of Science ®Google Scholar
• Weatherhead SC, Wahie S, Reynolds NJ, et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346–351.
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351–356.
   PubMed Web of Science ®Google Scholar
• Conway R, Low C, Coughlan RJ, et al. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum. 2015;45(2):156–162.
   PubMed Web of Science ®Google Scholar
• Gilani ST, Khan DA, Khan FA, et al. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012;22(2):101–104.
   PubMed Web of Science ®Google Scholar
• Lalani R, Lyu H, Vanni K, et al. Low-dose methotrexate and mucocutaneous adverse events: results of a systematic literature review and meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2020;72(8):1140–1146.
   PubMed Web of Science ®Google Scholar
• Park H. The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room. J Clin Aesthet Dermatol. 2011;4(1):18–27.
   PubMedGoogle Scholar
• Phan K, Smith SD. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat. 2020;31(8):810–814.
   PubMed Web of Science ®Google Scholar
• Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32(1):23–27.
   PubMed Web of Science ®Google Scholar
• Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385–391.
   PubMed Web of Science ®Google Scholar
• D’Ippolito D, Pisano M. Dupilumab (Dupixent): an Interleukin-4 receptor antagonist for atopic dermatitis. P T. 2018;43(9):532–535.
   PubMedGoogle Scholar
• Wang FP, Tang XJ, Wei CQ, et al., Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198.
   PubMed Web of Science ®Google Scholar
• Halling AS, Loft N, Silverberg JI, et al., Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139–147.
   PubMed Web of Science ®Google Scholar
• Han Y, Chen Y, Liu X, et al. Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2017;140(3):888–891.e6.
   PubMed Web of Science ®Google Scholar
• Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Deleuran M, et al. Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. J Dermatolog Treat. 2021;1–9. doi:https://doi.org/10.1080/09546634.2020.1871463.
   PubMed Web of Science ®Google Scholar
• Georgakopoulos JR, Felfeli T, Drucker AM, et al. Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study. JAAD Int. 2021; 4:67–69.
   PubMedGoogle Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503. e6.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(5):585–593.
   PubMed Web of Science ®Google Scholar
• Crisaborole for atopic dermatitis. Aust Prescr. 2019;42(6):211.
   PubMedGoogle Scholar
• Fahrbach K, Tarpey J, Washington EB, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis. Dermatol Ther (Heidelb). 2020;10(4):681–694.
   PubMed Web of Science ®Google Scholar
• Callender VD, Alexis AF, Stein Gold LF, et al. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups. Am J Clin Dermatol. 2019;20(5):711–723.
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275–284.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519–533.
   PubMed Web of Science ®Google Scholar
• Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2016;138(6):1719–1722.e1.
   PubMed Web of Science ®Google Scholar
• Hotze M, Baurecht H, Rodriguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 2014;69(1):132–135.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56(1):18–26.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study. Respir Med. 2017;130:55–60.
   PubMed Web of Science ®Google Scholar
• Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174(1):29–37.
   PubMed Web of Science ®Google Scholar
• Tsai HR, Lu JW, Chen LY, et al., Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021;11(4):279.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Singh R, Heron CE, Ghamrawi RI, et al. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:255–272.
   PubMed Web of Science ®Google Scholar
• Blauvelt A , Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047–1055 .
   Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823–831.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Mihara R, Kabashima K, Furue M, et al. Nemolizumab in moderate to severe atopic dermatitis: an exploratory analysis of work productivity and activity impairment in a randomized phase II study. J Dermatol. 2019;46(8):662–671.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141.
   PubMed Web of Science ®Google Scholar
• Zhou S, Qi F, Gong Y, et al. Biological therapies for atopic dermatitis: a systematic review. Dermatology. 2021;237(4):542–552.
   Web of Science ®Google Scholar